Cromos Pharma, where the patients are

Novo Nordisk

Novo Nordisk releases positive results in N8-GP trial

Thursday, March 20, 2014 03:22 PM

Novo Nordisk has completed pathfinder2, the first phase III trial with long-acting recombinant factor VIII, N8-GP (turoctocog alfa pegol) for hemophilia A patients. Pathfinder2 is a multi-national trial evaluating safety and efficacy of N8-GP, when administered for prophylaxis and on-demand treatment  in patients with hemophilia A, who are 12 years or older. 

More... »

CRF Health eCOA webinar series

Innate Pharma acquires ANTI-NKG2A from Novo Nordisk

Monday, February 10, 2014 10:19 AM

Innate Pharma has acquired full development and commercialization rights to the anti-NKG2A antibody, a first-in-class immune checkpoint inhibitor ready for phase II development in oncology from global healthcare company Novo Nordisk.

More... »


FDA approves Tretten to treat rare genetic clotting disorder

Tuesday, January 7, 2014 08:00 AM

The FDA has approved Tretten, Coagulation Factor XIII A-Subunit (Recombinant), the first recombinant product for use in the routine prevention of bleeding in adults and children who have a rare clotting disorder, known as congenital Factor XIII A-subunit deficiency.

More... »

Healthcare Leadership Council profiles inVentiv Health

Tuesday, November 26, 2013 10:00 AM

inVentiv Health, a global provider of best-in-class clinical, commercial and consulting services, has announced a cutting-edge inVentiv program for managing the care of chronic kidney disease has been included in a compilation of breakthrough innovations helping transform the American healthcare system.

More... »

Biogen Idec, Adimab expand collaboration

Friday, July 26, 2013 03:05 PM

Adimab, a provider of an integrated antibody discovery and optimization platform, has expanded its collaboration with Biogen Idec for the discovery of antibody-based therapeutics. 

More... »

Tresiba and Ryzodeg receive marketing authorizations in Europe

Wednesday, January 23, 2013 11:54 AM

The European Commission has granted marketing authorizations for Novo Nordisk’s Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) for the treatment of diabetes in adults.

More... »

Novo Nordisk to expand R&D center in China

Tuesday, September 25, 2012 09:58 AM

Novo Nordisk, a Denmark-based biopharmaceutical company and the first multinational company to open a research center in China in 1997, is reaffirming its long-term commitment to the country by investing an additional $100 million to expand its state-of-the-art science facilities in Beijing.

More... »

Regulus Therapeutics appoints Bruce Carter to board of directors

Wednesday, May 2, 2012 04:38 PM

Regulus Therapeutics, a biopharmaceutical company focused on medicines targeting microRNAs, has appointed Bruce Carter, Ph.D., to its board of directors.

More... »

Novo Nordisk licenses Caisson Biotech drug delivery tech

Wednesday, May 2, 2012 11:33 AM

Caisson Biotech, a subsidiary of Heparinex, has entered into a development and license agreement with Novo Nordisk, a global healthcare company based in Denmark.

More... »

Novo Nordisk plans 15% expansion of U.S. work force

Friday, April 27, 2012 01:36 PM

Novo Nordisk, a global healthcare company headquartered in Denmark, is planning a nearly 15% expansion of its U.S. work force in 2012.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 21

Healthcare IPOs soar in first quarter

Survey compares 'push/pull' tactics in patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs